Sarecycline Seysara denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sarecycline seysara are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Sarecycline (Seysara)

Blue Cross Blue Shield requires prior authorization (PA) for sarecycline before it will cover the prescription. This is not a denial of clinical appropriateness — it is a gatekeeping process that requires your prescriber to submit clinical information proving the prescription meets BCBS's coverage criteria before the claim is paid. If your prescription was dispensed and then denied because no PA was on file, or if your PA submission was denied, both situations are appealable.

### Why a PA Denial Is Appealable

Prior authorization criteria must be based on clinical evidence and applied consistently. If your clinical record meets the stated criteria — typically including a confirmed diagnosis, documented severity, and an adequate trial of required prior therapies — you are entitled to approval. A denial despite meeting the criteria, or a denial based on incomplete information that your prescriber can now supply, is a legitimate ground for appeal.

### Federal Appeal Framework

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/small-group plans), you may appeal any adverse benefit determination, including a PA denial. File within the deadline on the denial notice.
• External review: If the internal appeal is unsuccessful, request independent external review under ACA §2719 — generally available within approximately four months of the final internal decision.
• Peer-to-peer review: Your prescriber can request a peer-to-peer conversation with the BCBS medical director before or after filing a formal appeal; this is often the fastest path to resolution.
• Expedited review: Available when standard timelines would seriously jeopardize health; request it explicitly in writing.

### Concrete Appeal Steps

1. Obtain BCBS's prior authorization criteria document for sarecycline or acne antibiotics from the BCBS website or member services. 2. Review each criterion with your prescriber; identify which criterion BCBS says was not met. 3. Gather all clinical documentation that addresses the unmet criterion and have your prescriber prepare a targeted medical-necessity letter. 4. Request a peer-to-peer review if available — have the prescriber call BCBS's clinical review line. 5. If peer-to-peer does not resolve the issue, file the formal internal appeal with full documentation. 6. If denied internally, escalate to external review.

### Documentation to Gather

• Diagnosis confirmation: Chart notes confirming acne vulgaris diagnosis and severity classification.
• Prior-treatment history: Pharmacy records and visit notes for each required prior therapy (dates, durations, and documented reasons for stopping).
• Clinical severity documentation: Current chart notes showing active disease burden warranting systemic treatment.
• Prescriber medical-necessity letter: Addresses each PA criterion with a specific, dated chart fact.
• Criteria mapping: Two-column format — left column: each PA criterion verbatim from BCBS's policy; right column: the exact chart evidence satisfying it.

### Key Reminder

PA approvals are time-limited and medication-specific. Confirm the approval duration and note the expiration date. If you require ongoing therapy, initiate the renewal process before the current PA lapses to avoid a gap in coverage.